Compare Ascendis Pharma A/S (ASND) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Consumer Discretionary Select Sector SPDR Fund trades at $116.88. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| ASND | XLY | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | — |
52-Week High | $277.18 | $124.52 |
52-Week Low | $163.32 | $105.64 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
XLY trades at $117.24, up 0.33% today, with neutral technical signals from oscillators and a bearish moving average trend. Support levels are at $115 and $114, while resistance sits near $118. Analyst consensus is unanimously bullish with a 100% buy rating. Recent news highlights consumer discretionary sector strength amid inflation pressures and holiday spending trends.
The outlook for XLY is positive given strong analyst support, though technical indicators show mixed signals with near-term resistance. Risks include consumer sentiment erosion and inflation impacts on discretionary spending. Upside potential hinges on sustained economic growth and sector outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
